Skip to main content
HR 985 116th Congress House

FAST Generics Act of 2019

Official title: To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological … Show full official titleShow less

Official title: To amend the Federal Food, Drug, and Cosmetic Act to ensure that eligible product developers have competitive access to approved drugs and licensed biological products, so as to enable eligible product developers to develop and test new products, and for other purposes.

Introduced: May 20, 2019 Introduced by: Welch, Peter Democratic · Vermont See on congress.gov
Health Competition and antitrustDrug safety, medical device, and laboratory regulationLicensing and registrationsPrescription drugs
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Feb 5, 2019
Referred to the House Committee on Energy and Commerce.
Feb 5, 2019
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action February 5, 2019

Referred to the House Committee on Energy and Commerce.

 Plain-English summary Congressional Research Service

Fair Access for Safe and Timely Generics Act of 2019 or the FAST Generics Act of 2019

This bill generally prohibits the license holder of a drug or biological product approved by the Food and Drug Administration from restricting availability of the drug or product for testing by a product developer seeking to develop a drug, generic drug, or biosimilar.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 1
All 1 Democratic 1
D
Slotkin, Elissa
Michigan · May 20, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 985: FAST Generics Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-HR-985/
MLA
"H.R. 985: FAST Generics Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-HR-985/.
Bluebook (legal)
H.R. 985, 116th Cong. (2026), https://openamerica.io/bill/116-HR-985/.
Markdown link
[H.R. 985: FAST Generics Act of 2019](https://openamerica.io/bill/116-HR-985/)
Report a problem